In a report published Tuesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating on Stryker Corporation SYK, and raised the price target from $90.00 to $100.00.
In the report, Credit Suisse noted, “We're updating our 4Q14 sales/EPS estimates to $2.62B (8.6% CC, 5.6% organic)/$1.45 from $2.62B (8.0% CC, 4.6% organic)/$1.46 based on the company's early January preannouncement of $2.62B in sales & an EPS range of $1.43-$1.45. We're also adjusting our 2015 sales/EPS estimates to $9.92B (6.6% CC, 5.9% organic)/$5.09 from $10.18B (6.6% CC, 5.5% organic)/$5.21 on worsening Fx headwinds & slightly lower acquisition contribution partially offset by higher MedSurg estimates. Of note, SYK has implemented a transactional hedging program but does not hedge translational risk which it estimated was a $0.20 drag on 2015 EPS. Our updated estimates compare with 2015 consensus sales/EPS of $10.12B (4.5% YoY reported)/$5.14. We're also raising our DCF-based target price to $100 from $90 which implies an 18X P/E multiple on 2016 EPS which we believe is warranted given SYK's strong ~5%+ 2015-17 organic top-line growth trajectory.”
Stryker closed on Monday at $92.55.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in